Medacta Group Reports Growth in H1 2025

Medacta Group SA saw a significant rise in its adjusted EBITDA margin to 29.6% in constant currency during H1 2025. The company's revenue reached EUR 344.1 million, marking a 19.8% increase in constant currency. Adjusted EBITDA grew by 27.5% to EUR 98.8 million, and net profit rose by 58% to EUR 60.0 million.

Medacta attributes its success to innovations across all business lines and regions. The introduction of new products, such as the NextAR Rod Optimizer in the US and Japan, and the acquisition of Parcus Medical in Florida, enhanced its portfolio in sports medicine.

The company's revenue expansion was notable in Asia Pacific and North America, with significant gains in markets such as Australia, Japan, and the US. Medacta maintains a positive outlook, targeting a revenue growth of 16-18% and an adjusted EBITDA margin of around 28% for 2025.